Q2 2026 revenue rose 12% year-over-year to $3.3B, led by CF, CASGEVY, and JOURNAVX growth. Guidance for 2026 revenue was raised to $13.1–$13.2B, with at least $500M expected from non-CF products. The Crinetics acquisition and multiple regulatory milestones position the company for continued expansi…
Q2 2026 revenue rose 12% year-over-year to $3.3B, led by CF, CASGEVY, and JOURNAVX growth. Guidance for 2026 revenue was raised to $13.1–$13.2B, with at least $500M expected from non-CF products. The Crinetics acquisition and multiple regulatory milestones position the company for continued expansion.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
